BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

Jeffrey Alan Sosman; Adil Daud; Jeffrey S. Weber; Kevin Kim; Richard Kefford; Keith Flaherty; Jeffrey R. Infante; Omid Hamid; Jonathan S. Cebon; Lynn Mara Schuchter; Robert R. McWilliams; Mario Sznol; William Howard Sharfman; Alain Patrick Algazi; Karl D. Lewis; Shonda M. Little; Peng Sun; Georgina Long; Kiran Patel; Rene Gonzalez

doi:10.1200/jco.2013.31.15_suppl.9005

BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

Jeffrey Alan Sosman, Adil Daud, Jeffrey S. Weber, Kevin Kim, Richard Kefford, Keith Flaherty, Jeffrey R. Infante, Omid Hamid, Jonathan S. Cebon, Lynn Mara Schuchter, Robert R. McWilliams, Mario Sznol, William Howard Sharfman, Alain Patrick Algazi, Karl D. Lewis, Shonda M. Little, Peng Sun, Georgina Long, Kiran Patel, Rene Gonzalez

Faculty of Medicine, Health and Human Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	9005-9005
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	31
Issue number	15 supplement
DOIs	https://doi.org/10.1200/jco.2013.31.15_suppl.9005
Publication status	Published - 20 May 2013
Event	Annual Meeting of the American Society of Clinical Oncology (ASCO) - Chicago, United States Duration: 31 May 2013 → 4 Jun 2013

Access to Document

10.1200/jco.2013.31.15_suppl.9005

Cite this

Sosman, J. A., Daud, A., Weber, J. S., Kim, K., Kefford, R., Flaherty, K., Infante, J. R., Hamid, O., Cebon, J. S., Schuchter, L. M., McWilliams, R. R., Sznol, M., Sharfman, W. H., Algazi, A. P., Lewis, K. D., Little, S. M., Sun, P., Long, G., Patel, K., & Gonzalez, R. (2013). BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). Journal of Clinical Oncology, 31(15 supplement), 9005-9005. https://doi.org/10.1200/jco.2013.31.15_suppl.9005

@article{b8b0ee91838745658abab4a7d6132ea2,

title = "BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)",

author = "Sosman, {Jeffrey Alan} and Adil Daud and Weber, {Jeffrey S.} and Kevin Kim and Richard Kefford and Keith Flaherty and Infante, {Jeffrey R.} and Omid Hamid and Cebon, {Jonathan S.} and Schuchter, {Lynn Mara} and McWilliams, {Robert R.} and Mario Sznol and Sharfman, {William Howard} and Algazi, {Alain Patrick} and Lewis, {Karl D.} and Little, {Shonda M.} and Peng Sun and Georgina Long and Kiran Patel and Rene Gonzalez",

year = "2013",

month = may,

day = "20",

doi = "10.1200/jco.2013.31.15_suppl.9005",

language = "English",

volume = "31",

pages = "9005--9005",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "15 supplement",

note = "Annual Meeting of the American Society of Clinical Oncology (ASCO) ; Conference date: 31-05-2013 Through 04-06-2013",

}

Sosman, JA, Daud, A, Weber, JS, Kim, K, Kefford, R, Flaherty, K, Infante, JR, Hamid, O, Cebon, JS, Schuchter, LM, McWilliams, RR, Sznol, M, Sharfman, WH, Algazi, AP, Lewis, KD, Little, SM, Sun, P, Long, G, Patel, K & Gonzalez, R 2013, 'BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)', Journal of Clinical Oncology, vol. 31, no. 15 supplement, pp. 9005-9005. https://doi.org/10.1200/jco.2013.31.15_suppl.9005

BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). / Sosman, Jeffrey Alan; Daud, Adil; Weber, Jeffrey S. et al.
In: Journal of Clinical Oncology, Vol. 31, No. 15 supplement, 20.05.2013, p. 9005-9005.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

AU - Sosman, Jeffrey Alan

AU - Daud, Adil

AU - Weber, Jeffrey S.

AU - Kim, Kevin

AU - Kefford, Richard

AU - Flaherty, Keith

AU - Infante, Jeffrey R.

AU - Hamid, Omid

AU - Cebon, Jonathan S.

AU - Schuchter, Lynn Mara

AU - McWilliams, Robert R.

AU - Sznol, Mario

AU - Sharfman, William Howard

AU - Algazi, Alain Patrick

AU - Lewis, Karl D.

AU - Little, Shonda M.

AU - Sun, Peng

AU - Long, Georgina

AU - Patel, Kiran

AU - Gonzalez, Rene

PY - 2013/5/20

Y1 - 2013/5/20

U2 - 10.1200/jco.2013.31.15_suppl.9005

DO - 10.1200/jco.2013.31.15_suppl.9005

M3 - Meeting abstract

SN - 0732-183X

VL - 31

SP - 9005

EP - 9005

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15 supplement

T2 - Annual Meeting of the American Society of Clinical Oncology (ASCO)

Y2 - 31 May 2013 through 4 June 2013

ER -

Sosman JA, Daud A, Weber JS, Kim K, Kefford R, Flaherty K et al. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). Journal of Clinical Oncology. 2013 May 20;31(15 supplement):9005-9005. doi: 10.1200/jco.2013.31.15_suppl.9005